Moleculin Biotech receives Hong Kong patent for Annamycin reconstitution method
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin
May 8, 2026 8:45 AM EDTSolid Intellectual Property Protection Across Four Continents Ahead of Pending Phase 3 Data Release
HOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), today announced a significant advancement in its intellectual property portfolio with the issuance of a Hong Kong patent covering its proprietary method of reconstituting liposomal Annamycin.
The newly granted patent (No. 40073244), titled Method of Reconstituting Liposomal Annamycin, extends protection through June 25, 2040, further reinforcing Moleculins long-term global exclusivity strategy. The invention is jointly owned with The University of... More
